Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats

Ubiquitin C‐terminal hydrolase‐L1 (UCH‐L1), also called neuronal‐specific protein gene product 9.5, is a highly abundant protein in the neuronal cell body and has been identified as a possible biomarker on the basis of a recent proteomic study. In this study, we examined whether UCH‐L1 was significa...

Full description

Saved in:
Bibliographic Details
Published inThe European journal of neuroscience Vol. 31; no. 4; pp. 722 - 732
Main Authors Liu, Ming C., Akinyi, Linnet, Scharf, Dancia, Mo, Jixiang, Larner, Stephen F., Muller, Uwe, Oli, Monika W., Zheng, Wenrong, Kobeissy, Firas, Papa, Linda, Lu, Xi-Chun, Dave, Jitendra R., Tortella, Frank C., Hayes, Ronald L., Wang, Kevin K. W.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.02.2010
Subjects
Animals
biomarker
Biomarkers - blood
Biomarkers - cerebrospinal fluid
Brain - metabolism
Brain Injuries - blood
Brain Injuries - cerebrospinal fluid
cell death
diagnosis
Disease Models, Animal
Infarction, Middle Cerebral Artery - blood
Infarction, Middle Cerebral Artery - cerebrospinal fluid
ischemia
Male
Rats
Rats, Sprague-Dawley
Spectrin - cerebrospinal fluid
stroke
traumatic brain injury
Ubiquitin Thiolesterase - blood
Ubiquitin Thiolesterase - cerebrospinal fluid
Online AccessGet full text

Cover

Abstract Ubiquitin C‐terminal hydrolase‐L1 (UCH‐L1), also called neuronal‐specific protein gene product 9.5, is a highly abundant protein in the neuronal cell body and has been identified as a possible biomarker on the basis of a recent proteomic study. In this study, we examined whether UCH‐L1 was significantly elevated in cerebrospinal fluid (CSF) following controlled cortical impact (CCI) and middle cerebral artery occlusion (MCAO; model of ischemic stroke) in rats. Quantitative immunoblots of rat CSF revealed a dramatic elevation of UCH‐L1 protein 48 h after severe CCI and as early as 6 h after mild (30 min) and severe (2 h) MCAO. A sandwich enzyme‐linked immunosorbent assay constructed to measure UCH‐L1 sensitively and quantitatively showed that CSF UCH‐L1 levels were significantly elevated as early as 2 h and up to 48 h after CCI. Similarly, UCH‐L1 levels were also significantly elevated in CSF from 6 to 72 h after 30 min of MCAO and from 6 to 120 h after 2 h of MCAO. These data are comparable to the profile of the calpain‐produced αII‐spectrin breakdown product of 145 kDa biomarker. Importantly, serum UCH‐L1 biomarker levels were also significantly elevated after CCI. Similarly, serum UCH‐L1 levels in the 2‐h MCAO group were significantly higher than those in the 30‐min group. Taken together, these data from two rat models of acute brain injury strongly suggest that UCH‐L1 is a candidate brain injury biomarker detectable in biofluid compartments (CSF and serum).
AbstractList AbstractUbiquitin C-terminal hydrolase-L1 (UCH-L1), also called neuronal-specific protein gene product 9.5, is a highly abundant protein in the neuronal cell body and has been identified as a possible biomarker on the basis of a recent proteomic study. In this study, we examined whether UCH-L1 was significantly elevated in cerebrospinal fluid (CSF) following controlled cortical impact (CCI) and middle cerebral artery occlusion (MCAO; model of ischemic stroke) in rats. Quantitative immunoblots of rat CSF revealed a dramatic elevation of UCH-L1 protein 48 h after severe CCI and as early as 6 h after mild (30 min) and severe (2 h) MCAO. A sandwich enzyme-linked immunosorbent assay constructed to measure UCH-L1 sensitively and quantitatively showed that CSF UCH-L1 levels were significantly elevated as early as 2 h and up to 48 h after CCI. Similarly, UCH-L1 levels were also significantly elevated in CSF from 6 to 72 h after 30 min of MCAO and from 6 to 120 h after 2 h of MCAO. These data are comparable to the profile of the calpain-produced alpha II-spectrin breakdown product of 145 kDa biomarker. Importantly, serum UCH-L1 biomarker levels were also significantly elevated after CCI. Similarly, serum UCH-L1 levels in the 2-h MCAO group were significantly higher than those in the 30-min group. Taken together, these data from two rat models of acute brain injury strongly suggest that UCH-L1 is a candidate brain injury biomarker detectable in biofluid compartments (CSF and serum).
Ubiquitin C‐terminal hydrolase‐L1 (UCH‐L1), also called neuronal‐specific protein gene product 9.5, is a highly abundant protein in the neuronal cell body and has been identified as a possible biomarker on the basis of a recent proteomic study. In this study, we examined whether UCH‐L1 was significantly elevated in cerebrospinal fluid (CSF) following controlled cortical impact (CCI) and middle cerebral artery occlusion (MCAO; model of ischemic stroke) in rats. Quantitative immunoblots of rat CSF revealed a dramatic elevation of UCH‐L1 protein 48 h after severe CCI and as early as 6 h after mild (30 min) and severe (2 h) MCAO. A sandwich enzyme‐linked immunosorbent assay constructed to measure UCH‐L1 sensitively and quantitatively showed that CSF UCH‐L1 levels were significantly elevated as early as 2 h and up to 48 h after CCI. Similarly, UCH‐L1 levels were also significantly elevated in CSF from 6 to 72 h after 30 min of MCAO and from 6 to 120 h after 2 h of MCAO. These data are comparable to the profile of the calpain‐produced αII‐spectrin breakdown product of 145 kDa biomarker. Importantly, serum UCH‐L1 biomarker levels were also significantly elevated after CCI. Similarly, serum UCH‐L1 levels in the 2‐h MCAO group were significantly higher than those in the 30‐min group. Taken together, these data from two rat models of acute brain injury strongly suggest that UCH‐L1 is a candidate brain injury biomarker detectable in biofluid compartments (CSF and serum).
Ubiquitin C-terminal hydrolase-L1 (UCH-L1), also called neuronal-specific protein gene product 9.5, is a highly abundant protein in the neuronal cell body and has been identified as a possible biomarker on the basis of a recent proteomic study. In this study, we examined whether UCH-L1 was significantly elevated in cerebrospinal fluid (CSF) following controlled cortical impact (CCI) and middle cerebral artery occlusion (MCAO; model of ischemic stroke) in rats. Quantitative immunoblots of rat CSF revealed a dramatic elevation of UCH-L1 protein 48 h after severe CCI and as early as 6 h after mild (30 min) and severe (2 h) MCAO. A sandwich enzyme-linked immunosorbent assay constructed to measure UCH-L1 sensitively and quantitatively showed that CSF UCH-L1 levels were significantly elevated as early as 2 h and up to 48 h after CCI. Similarly, UCH-L1 levels were also significantly elevated in CSF from 6 to 72 h after 30 min of MCAO and from 6 to 120 h after 2 h of MCAO. These data are comparable to the profile of the calpain-produced alphaII-spectrin breakdown product of 145 kDa biomarker. Importantly, serum UCH-L1 biomarker levels were also significantly elevated after CCI. Similarly, serum UCH-L1 levels in the 2-h MCAO group were significantly higher than those in the 30-min group. Taken together, these data from two rat models of acute brain injury strongly suggest that UCH-L1 is a candidate brain injury biomarker detectable in biofluid compartments (CSF and serum).
Ubiquitin C-terminal hydrolase-L1 (UCH-L1), also called neuronal-specific protein gene product 9.5, is a highly abundant protein in the neuronal cell body and has been identified as a possible biomarker on the basis of a recent proteomic study. In this study, we examined whether UCH-L1 was significantly elevated in cerebrospinal fluid (CSF) following controlled cortical impact (CCI) and middle cerebral artery occlusion (MCAO; model of ischemic stroke) in rats. Quantitative immunoblots of rat CSF revealed a dramatic elevation of UCH-L1 protein 48 h after severe CCI and as early as 6 h after mild (30 min) and severe (2 h) MCAO. A sandwich enzyme-linked immunosorbent assay constructed to measure UCH-L1 sensitively and quantitatively showed that CSF UCH-L1 levels were significantly elevated as early as 2 h and up to 48 h after CCI. Similarly, UCH-L1 levels were also significantly elevated in CSF from 6 to 72 h after 30 min of MCAO and from 6 to 120 h after 2 h of MCAO. These data are comparable to the profile of the calpain-produced alphaII-spectrin breakdown product of 145 kDa biomarker. Importantly, serum UCH-L1 biomarker levels were also significantly elevated after CCI. Similarly, serum UCH-L1 levels in the 2-h MCAO group were significantly higher than those in the 30-min group. Taken together, these data from two rat models of acute brain injury strongly suggest that UCH-L1 is a candidate brain injury biomarker detectable in biofluid compartments (CSF and serum).Ubiquitin C-terminal hydrolase-L1 (UCH-L1), also called neuronal-specific protein gene product 9.5, is a highly abundant protein in the neuronal cell body and has been identified as a possible biomarker on the basis of a recent proteomic study. In this study, we examined whether UCH-L1 was significantly elevated in cerebrospinal fluid (CSF) following controlled cortical impact (CCI) and middle cerebral artery occlusion (MCAO; model of ischemic stroke) in rats. Quantitative immunoblots of rat CSF revealed a dramatic elevation of UCH-L1 protein 48 h after severe CCI and as early as 6 h after mild (30 min) and severe (2 h) MCAO. A sandwich enzyme-linked immunosorbent assay constructed to measure UCH-L1 sensitively and quantitatively showed that CSF UCH-L1 levels were significantly elevated as early as 2 h and up to 48 h after CCI. Similarly, UCH-L1 levels were also significantly elevated in CSF from 6 to 72 h after 30 min of MCAO and from 6 to 120 h after 2 h of MCAO. These data are comparable to the profile of the calpain-produced alphaII-spectrin breakdown product of 145 kDa biomarker. Importantly, serum UCH-L1 biomarker levels were also significantly elevated after CCI. Similarly, serum UCH-L1 levels in the 2-h MCAO group were significantly higher than those in the 30-min group. Taken together, these data from two rat models of acute brain injury strongly suggest that UCH-L1 is a candidate brain injury biomarker detectable in biofluid compartments (CSF and serum).
Author Wang, Kevin K. W.
Papa, Linda
Hayes, Ronald L.
Mo, Jixiang
Liu, Ming C.
Larner, Stephen F.
Muller, Uwe
Zheng, Wenrong
Oli, Monika W.
Lu, Xi-Chun
Tortella, Frank C.
Scharf, Dancia
Kobeissy, Firas
Akinyi, Linnet
Dave, Jitendra R.
Author_xml – sequence: 1
  givenname: Ming C.
  surname: Liu
  fullname: Liu, Ming C.
  organization: Center of Innovative Research, Banyan Biomarkers, Inc., 12085 Research Drive, Alachua, FL 32615, USA
– sequence: 2
  givenname: Linnet
  surname: Akinyi
  fullname: Akinyi, Linnet
  organization: Diagnostic Research and Development Department, Banyan Biomarkers, Inc., Alachua, FL, USA
– sequence: 3
  givenname: Dancia
  surname: Scharf
  fullname: Scharf, Dancia
  organization: Diagnostic Research and Development Department, Banyan Biomarkers, Inc., Alachua, FL, USA
– sequence: 4
  givenname: Jixiang
  surname: Mo
  fullname: Mo, Jixiang
  organization: Diagnostic Research and Development Department, Banyan Biomarkers, Inc., Alachua, FL, USA
– sequence: 5
  givenname: Stephen F.
  surname: Larner
  fullname: Larner, Stephen F.
  organization: Center of Innovative Research, Banyan Biomarkers, Inc., 12085 Research Drive, Alachua, FL 32615, USA
– sequence: 6
  givenname: Uwe
  surname: Muller
  fullname: Muller, Uwe
  organization: Diagnostic Research and Development Department, Banyan Biomarkers, Inc., Alachua, FL, USA
– sequence: 7
  givenname: Monika W.
  surname: Oli
  fullname: Oli, Monika W.
  organization: Diagnostic Research and Development Department, Banyan Biomarkers, Inc., Alachua, FL, USA
– sequence: 8
  givenname: Wenrong
  surname: Zheng
  fullname: Zheng, Wenrong
  organization: Center of Innovative Research, Banyan Biomarkers, Inc., 12085 Research Drive, Alachua, FL 32615, USA
– sequence: 9
  givenname: Firas
  surname: Kobeissy
  fullname: Kobeissy, Firas
  organization: Center for Neuroproteomics and Biomarkers Research, Department of Psychiatry, McKnight Brain Institute, University of Florida, Gainesville, FL, USA
– sequence: 10
  givenname: Linda
  surname: Papa
  fullname: Papa, Linda
  organization: Department of Emergency Medicine, Orlando Regional Medical Center, Orlando, FL, USA
– sequence: 11
  givenname: Xi-Chun
  surname: Lu
  fullname: Lu, Xi-Chun
  organization: Department of Applied Neurobiology, Division of Psychiatry and Neuroscience, Walter Reed Army Institute of Research, Silver Spring, MD, USA
– sequence: 12
  givenname: Jitendra R.
  surname: Dave
  fullname: Dave, Jitendra R.
  organization: Department of Applied Neurobiology, Division of Psychiatry and Neuroscience, Walter Reed Army Institute of Research, Silver Spring, MD, USA
– sequence: 13
  givenname: Frank C.
  surname: Tortella
  fullname: Tortella, Frank C.
  organization: Department of Applied Neurobiology, Division of Psychiatry and Neuroscience, Walter Reed Army Institute of Research, Silver Spring, MD, USA
– sequence: 14
  givenname: Ronald L.
  surname: Hayes
  fullname: Hayes, Ronald L.
  organization: Center of Innovative Research, Banyan Biomarkers, Inc., 12085 Research Drive, Alachua, FL 32615, USA
– sequence: 15
  givenname: Kevin K. W.
  surname: Wang
  fullname: Wang, Kevin K. W.
  organization: Center of Innovative Research, Banyan Biomarkers, Inc., 12085 Research Drive, Alachua, FL 32615, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20384815$$D View this record in MEDLINE/PubMed
BookMark eNqNUU1PGzEUtCqqEmj_QuUTnDa11597KBKKgLZE6QVabq_eXVs43Y9g74rk39fbAIceKnx59vPM-HnmCB10fWcRwpTMaVqf1nPKJckKIfU8J6lLFCnUfPsGzV4uDtCMFIJlmsq7Q3QU45oQoiUX79BhTpjmmooZ-nVb-ofRD77Di2ywofWdafD9rg59Y6LNlhSbiA0ufd-a8NsG7PqAfazubesrbLoaD8GMrRnSqQwm6fhuPYZdKjiYIb5Hb51pov3wVI_R7eXFzeJLtvx-9XVxvswqrpXKlLG1q5yreZ6XpmKa6JxrR5kkteaW08IJIwlTrOA50SWhglc1VaJgTjqj2DE63etuQv8w2jhAm6a0TWM6248RFGPp75LrhDz5LzKnYnIqT8CPT8CxbG0Nm-CTBzt4di8BzvaAKvQxBuug8kNyou-SJ74BSmCKC9YwpQJTKjDFBX_jgm0S0P8IPL_xCurnPfXRN3b3ah5cfFtNu8TP9nwfB7t94aeMQSqmBPxcXYG8vv5xc7dcgWR_ADQ5utY
CitedBy_id crossref_primary_10_1002_jnr_24054
crossref_primary_10_1007_s00415_023_12160_9
crossref_primary_10_3390_biomedicines12030608
crossref_primary_10_1016_j_clinbiochem_2013_09_015
crossref_primary_10_2174_1573405618666220321122214
crossref_primary_10_1097_PCC_0b013e3182720642
crossref_primary_10_1016_j_ajem_2015_05_023
crossref_primary_10_1089_neu_2010_1653
crossref_primary_10_1093_toxsci_kfs224
crossref_primary_10_1007_s11682_012_9156_5
crossref_primary_10_1586_erm_10_104
crossref_primary_10_1080_02699052_2017_1382717
crossref_primary_10_1007_s12035_022_02775_w
crossref_primary_10_1089_neu_2015_3873
crossref_primary_10_3390_ijms25031658
crossref_primary_10_1002_glia_22690
crossref_primary_10_1038_s41598_018_21063_z
crossref_primary_10_2119_molmed_2011_00259
crossref_primary_10_33808_clinexphealthsci_943779
crossref_primary_10_1080_14737159_2018_1428089
crossref_primary_10_1007_s00701_016_3046_3
crossref_primary_10_3171_2018_4_PEDS17593
crossref_primary_10_1016_j_trprot_2013_07_001
crossref_primary_10_1007_s12028_014_0028_2
crossref_primary_10_1016_j_wneu_2013_03_012
crossref_primary_10_1097_TA_0b013e31822117fe
crossref_primary_10_1136_jramc_2015_000517
crossref_primary_10_1089_neu_2011_1754
crossref_primary_10_1080_14728222_2017_1321635
crossref_primary_10_3390_diagnostics14121245
crossref_primary_10_1089_neu_2018_5809
crossref_primary_10_1111_jcmm_13275
crossref_primary_10_5507_bp_2024_038
crossref_primary_10_1089_neu_2011_1989
crossref_primary_10_3389_fphar_2023_1272969
crossref_primary_10_1038_s41393_019_0319_8
crossref_primary_10_3389_fneur_2014_00273
crossref_primary_10_14336_AD_2017_0602
crossref_primary_10_17116_neiro201579190_96
crossref_primary_10_1089_neu_2012_2762
crossref_primary_10_1016_j_brainres_2018_09_028
crossref_primary_10_3389_fneur_2016_00198
crossref_primary_10_1016_j_bas_2024_104173
crossref_primary_10_1002_elps_201200196
crossref_primary_10_1007_s12035_022_02822_6
crossref_primary_10_1007_s12028_022_01461_y
crossref_primary_10_1016_j_omtm_2022_03_017
crossref_primary_10_1097_ACO_0b013e32834585d6
crossref_primary_10_1080_14737159_2024_2306876
crossref_primary_10_1021_pr200673y
crossref_primary_10_1371_journal_pone_0092698
crossref_primary_10_1039_C4AN01935K
crossref_primary_10_1038_s41598_024_61363_1
crossref_primary_10_1080_02699052_2017_1418907
crossref_primary_10_4155_tde_2022_0064
crossref_primary_10_1016_j_jprot_2015_01_009
crossref_primary_10_3390_life15030495
crossref_primary_10_3171_2012_10_JNS12725
crossref_primary_10_1016_j_jtcvs_2011_06_027
crossref_primary_10_1186_1471_2377_12_85
crossref_primary_10_1186_s40779_021_00363_y
crossref_primary_10_1089_neu_2012_2825
crossref_primary_10_1093_bja_aer338
crossref_primary_10_1371_journal_pone_0028938
crossref_primary_10_3390_neuroglia5040024
crossref_primary_10_1111_ane_13668
crossref_primary_10_1016_j_jocn_2021_10_015
crossref_primary_10_1177_2059700216684518
crossref_primary_10_1097_PAF_0000000000000103
crossref_primary_10_1007_s12031_020_01536_5
crossref_primary_10_1161_CIRCRESAHA_122_320110
crossref_primary_10_1002_ams2_622
crossref_primary_10_3390_ijms241310902
crossref_primary_10_3389_fneur_2021_634717
crossref_primary_10_1089_neu_2011_2127
crossref_primary_10_1089_neu_2015_3881
crossref_primary_10_25692_ACEN_2020_4_2
crossref_primary_10_3109_02699052_2015_1079733
crossref_primary_10_1016_j_jtemb_2024_127506
crossref_primary_10_1371_journal_pone_0096296
crossref_primary_10_1016_j_nbd_2018_07_017
crossref_primary_10_1093_milmed_usz185
crossref_primary_10_1016_j_brainres_2013_09_051
crossref_primary_10_3390_jcm11133700
crossref_primary_10_1093_milmed_usad433
crossref_primary_10_1111_1440_1681_13216
crossref_primary_10_1002_elps_201200326
crossref_primary_10_3390_biomedicines11030855
crossref_primary_10_3389_fneur_2021_755152
crossref_primary_10_1016_j_bbi_2024_11_015
crossref_primary_10_1146_annurev_anchem_062011_143105
crossref_primary_10_1038_srep24588
crossref_primary_10_1089_neu_2012_2683
crossref_primary_10_1093_toxsci_kfv188
crossref_primary_10_3389_fneur_2015_00047
crossref_primary_10_1007_s12975_011_0137_6
crossref_primary_10_1016_j_ajem_2017_06_032
crossref_primary_10_1186_1559_0275_11_11
crossref_primary_10_3390_bios7030030
crossref_primary_10_1074_mcp_M116_058115
crossref_primary_10_1097_TA_0b013e3182491e3d
crossref_primary_10_1016_j_clinbiochem_2014_01_028
crossref_primary_10_2217_bmm_2021_0284
crossref_primary_10_3389_fneur_2019_00124
crossref_primary_10_1016_j_eplepsyres_2012_08_001
crossref_primary_10_1089_neu_2010_1564
crossref_primary_10_1016_j_resuscitation_2020_05_016
Cites_doi 10.1095/biolreprod.104.037077
10.1016/S0166-2236(99)01401-0
10.1021/bi960099f
10.1016/S0006-8993(02)02920-7
10.1016/S0197-0186(00)00040-1
10.1002/prca.200800011
10.1523/JNEUROSCI.09-05-01579.1989
10.1016/0022-510X(81)90032-0
10.1097/00001756-199808030-00002
10.1097/CCM.0b013e3181b788ab
10.1016/j.jim.2006.09.021
10.1373/49.10.1752
10.1111/j.1749-6632.1993.tb18290.x
10.1016/0006-8993(88)91222-X
10.1093/bja/aeg225
10.1016/j.jns.2005.03.015
10.1089/089771500415391
10.1074/mcp.M600157-MCP200
10.1161/STROKEAHA.107.487108
10.1161/01.STR.28.10.1956
10.1089/neu.2004.21.1553
10.1128/MCB.20.13.4691-4698.2000
10.1021/bi972274d
10.1038/nn930
10.1080/02688699944195
10.1038/12647
10.1016/j.brainres.2008.03.034
10.3233/JAD-2007-11203
10.1016/0896-6273(88)90076-1
10.1089/neu.2007.0316
10.1586/14789450.2.4.603
10.1136/jnnp.2005.085175
10.1089/neu.2006.003789
10.1038/sj.jcbfm.9600138
10.1093/emboj/18.14.3877
10.1016/j.nbd.2004.03.016
10.1016/S0003-4975(99)01393-4
10.1080/02688699647104
10.1067/mem.2002.121214
10.1097/01.shk.0000168876.68154.43
10.1046/j.1471-4159.2001.00510.x
10.1096/fasebj.11.14.9409543
10.1179/016164101101198325
10.1097/00004647-200107000-00012
10.1016/0006-8993(89)90921-9
10.1016/0090-3019(95)80012-6
10.1212/01.WNL.0000120550.00643.DC
10.1034/j.1600-0404.2001.00053.x
10.1007/s00701-007-1489-2
10.1016/j.bbrc.2005.08.252
10.1042/bst0200631
10.1542/peds.2005-0711
10.1097/01.TA.0000108998.48026.C3
10.1097/TA.0b013e318185db2d
10.1097/NEN.0b013e3181996bfe
10.1089/neu.2004.21.1443
10.1097/00001756-199902050-00040
10.1097/01.WCB.0000098520.11962.37
10.1097/01.shk.0000101672.49265.14
10.1089/neu.2007.0488
10.1016/j.physbeh.2003.06.001
ContentType Journal Article
Copyright The Authors (2010). Journal Compilation © Federation of European Neuroscience Societies and Blackwell Publishing Ltd
Copyright_xml – notice: The Authors (2010). Journal Compilation © Federation of European Neuroscience Societies and Blackwell Publishing Ltd
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7X8
DOI 10.1111/j.1460-9568.2010.07097.x
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList Neurosciences Abstracts

MEDLINE
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
EISSN 1460-9568
EndPage 732
ExternalDocumentID 20384815
10_1111_j_1460_9568_2010_07097_x
EJN7097
ark_67375_WNG_6KKVTXLN_6
Genre article
Research Support, U.S. Gov't, Non-P.H.S
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NINDS NIH HHS
  grantid: R44 NS048685
– fundername: NINDS NIH HHS
  grantid: R01 NS049175-01 A1
– fundername: NINDS NIH HHS
  grantid: R01 NS049175
– fundername: NINDS NIH HHS
  grantid: 2R44NS048685-02
GroupedDBID ---
-~X
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
29G
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABIVO
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHEFC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
EAD
EAP
EAS
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EPS
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GAKWD
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
Q~Q
R.K
RIG
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WHG
WIH
WIJ
WIK
WNSPC
WOHZO
WOW
WQJ
WRC
WUP
WXI
WXSBR
WYISQ
XG1
YFH
ZGI
ZZTAW
~IA
~WT
AAHQN
AAIPD
AAMNL
AANHP
AAYCA
ACRPL
ACUHS
ACYXJ
ADNMO
AFWVQ
ALVPJ
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
7X8
ID FETCH-LOGICAL-c4877-7aedfcffd422bac3808248f1360d84e419f5a6037394208b0154cd17593f6fa73
IEDL.DBID DR2
ISSN 0953-816X
1460-9568
IngestDate Fri Jul 11 11:27:18 EDT 2025
Fri Jul 11 15:24:43 EDT 2025
Sat May 31 02:12:25 EDT 2025
Tue Jul 01 04:00:27 EDT 2025
Thu Apr 24 23:02:22 EDT 2025
Wed Jan 22 16:58:38 EST 2025
Wed Oct 30 10:06:04 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4877-7aedfcffd422bac3808248f1360d84e419f5a6037394208b0154cd17593f6fa73
Notes istex:0CF479FA55D8CD11E69EE3EDC8EA67A8B1D43129
ArticleID:EJN7097
ark:/67375/WNG-6KKVTXLN-6
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/2855688
PMID 20384815
PQID 21500082
PQPubID 23462
PageCount 11
ParticipantIDs proquest_miscellaneous_733645648
proquest_miscellaneous_21500082
pubmed_primary_20384815
crossref_citationtrail_10_1111_j_1460_9568_2010_07097_x
crossref_primary_10_1111_j_1460_9568_2010_07097_x
wiley_primary_10_1111_j_1460_9568_2010_07097_x_EJN7097
istex_primary_ark_67375_WNG_6KKVTXLN_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-02
February 2010
2010-02-00
2010-Feb
20100201
PublicationDateYYYYMMDD 2010-02-01
PublicationDate_xml – month: 02
  year: 2010
  text: 2010-02
PublicationDecade 2010
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: France
PublicationTitle The European journal of neuroscience
PublicationTitleAlternate Eur J Neurosci
PublicationYear 2010
Publisher Blackwell Publishing Ltd
Publisher_xml – name: Blackwell Publishing Ltd
References Missler, U., Wiesmann, M., Friedrich, C. & Kaps, M. (1997) S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke, 28, 1956-1960.
Pike, B.R., Flint, J., Johnson, E., Glenn, C.C., Dutta, S., Wang, K.K.W. & Hayes, R.L. (2001) Accumulation of calpain-cleaved non-erythroid αII-spectrin in cerebrospinal fluid after traumatic brain injury in rats. J. Neurochem., 78, 1297-1306.
Petzold, A. (2005) Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J. Neurol. Sci., 233, 183-198.
Shaw, G., Yang, C., Ellis, R., Anderson, K., Parker Mickle, J., Scheff, S., Pike, B., Anderson, D.K. & Howland, D.R. (2005) Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem. Biophys. Res. Commun., 336, 1268-1277.
Berger, R.P., Beers, S.R., Richichi, R., Wiesman, D. & Adelson, P.D. (2007) Serum biomarker concentrations and outcome after pediatric traumatic brain injury. J. Neurotrauma, 24, 1793-1801.
Kobeissy, F.H., Sadasivan, S., Oli, M.W., Robinson, G., Larner, S.F., Zhang, Z., Hayes, R.L. & Wang, K.K.W. (2008) Neuroproteomics and systems biology-based discovery of protein biomarkers for traumatic brain injury and clinical validation. Proteomics Clin. Appl. 2, 1467-1483.
McGinn, M.J., Kelley, B.J., Akinyi, L., Oli, M.W., Liu, M.C., Hayes, R.L., Wang, K.K.W. & Povlishock, J.T. (2009) Biochemical, structural and biomarker evidence for calpain-mediated cytoskeletal change following diffuse brain injury uncomplicated by contusion. J. Neuropathol. Exp. Neurol., 68, 241-249.
Pike, B.R., Zhao, X., Newcomb, J.K., Posmantur, R.M., Wang, K.K. & Hayes, R.L. (1998) Regional calpain and caspase-3 proteolysis of alpha-spectrin after traumatic brain injury. Neuroreport, 9, 2437-2442.
Petzold, A., Keir, G., Kay, A., Kerr, M. & Thompson, E.J. (2006) Axonal damage and outcome in subarachnoid haemorrhage. J. Neurol. Neurosurg. Psychiatry, 77, 753-759.
Lumpkins, K.M., Bochicchio, G.V., Keledjian, K., Simard, J.M., McCunn, M. & Scalea, T. (2008) Glial fibrillary acidic protein is highly correlated with brain injury. J. Trauma, 65, 778-784.
Roberts-Lewis, J.M. & Siman, R. (1993) Spectrin proteolysis in the hippocampus: a biochemical marker for neuronal injury and neuroprotection. Ann. N Y Acad. Sci., 679, 78-86.
Petzold, A. & Shaw, G. (2007) Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain. J. Immunol. Methods, 319, 34-40.
Larsen, C.N., Price, J.S. & Wilkinson, K.D. (1996) Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry, 35, 6735-6744.
Pelinka, L.E., Kroepfl, A., Leixnering, M., Buchinger, W., Raabe, A. & Redl, H. (2004b) GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J. Neurotrauma, 21, 1553-1561.
Romner, B., Ingebrigtsen, T., Kongstad, P. & Borgesen, S.E. (2000) Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings. J. Neurotrauma, 17, 641-647.
Shaw, G.J., Jauch, E.C. & Zemlan, F.P. (2002) Serum cleaved tau protein levels and clinical outcome in adult patients with closed head injury. Ann. Emerg. Med., 39, 254-257.
Berger, R.P., Dulani, T., Adelson, P.D., Leventhal, J.M., Richichi, R. & Kochanek, P.M. (2006) Identification of inflicted traumatic brain injury in well-appearing infants using serum and cerebrospinal markers: a possible screening tool. Pediatrics, 117, 325-332.
Pelinka, L.E., Hertz, H., Mauritz, W., Harada, N., Jafarmadar, M., Albrecht, M., Redl, H. & Bahrami, S. (2005) Nonspecific increase of systemic neuron-specific enolase after trauma: clinical and experimental findings. Shock, 24, 119-123.
Seubert, P., Lee, K. & Lynch, G. (1989) Ischemia triggers NMDA receptor-linked cytoskeletal proteolysis in hippocampus. Brain Res., 492, 366-370.
Pelinka, L.E., Harada, N., Szalay, L., Jafarmadar, M., Redl, H. & Bahrami, S. (2004c) Release of S100B differs during ischemia and reperfusion of the liver, the gut, and the kidney in rats. Shock, 21, 72-76.
Anderson, K.J., Scheff, S.W., Miller, K.M., Roberts, K.N., Gilmer, L.K., Yang, C. & Shaw, G. (2008) The phosphorylated axonal form of the neurofilament subunit NF-H (pNF-H) as a blood biomarker of traumatic brain injury. J. Neurotrauma, 25, 1079-1085.
Pelinka, L.E., Kroepfl, A., Schmidhammer, R., Krenn, M., Buchinger, W., Redl, H. & Raabe, A. (2004a) Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J. Trauma, 57, 1006-1012.
Vos, P.E., Lamers, K.J., Hendriks, J.C., Van Haaren, M., Beems, T., Zimmerman, C., Van Geel, W., De Reus, H., Biert, J. & Verbeek, M.M. (2004) Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology, 62, 1303-1310.
Ringger, N.C., O' Steen, B.E., Brabham, J.G., Silver, X., Pineda, J., Wang, K.K.W. & Hayes, R.L. (2005) A novel marker for traumatic brain injury: CSF αII-spectrin breakdown product levels. J. Neurotrauma, 21, 1443-1456.
Siman, R., McIntosh, T.K., Soltesz, K.M., Chen, Z., Neumar, R.W. & Roberts, V.L. (2004) Proteins released from degenerating neurons are surrogate markers for acute brain damage. Neurobiol. Dis., 16, 311-320.
Yamazaki, Y., Yada, K., Morii, S., Kitahara, T. & Ohwada, T. (1995) Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. Surg. Neurol., 43, 267-270.
Wilkinson, K.D. (1997) Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J., 11, 1245-1256.
Hu, B.R., Janelidze, S., Ginsberg, M.D., Busto, R., Perez-Pinzon, M., Sick, T.J., Siesjö, B.K. & Liu, C.L. (2001) Protein aggregation after focal brain ischemia and reperfusion. J. Cereb. Blood Flow Metab., 21, 865-875.
Wang, K.K.W., Ottens, A., Liu, M.C., Lewis, S.B., Meegan, C., Oli, M.W., Tortella, F.C. & Hayes, R.L. (2005) Proteomic identification of biomarkers of traumatic brain injury. Expert Rev. Proteomics, 2, 603-614.
Berger, R.P., Adelson, P.D., Pierce, M.C., Dulani, T., Cassidy, L.D. & Kochanek, P.M. (2005) Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J. Neurosurg., 103(1 Suppl.), 61-68.
Elkind, M.S. (2003) Stroke in the elderly. Mt. Sinai J. Med., 70, 27-37.
Lincoln, S., Vaughan, J., Wood, N., Baker, M., Adamson, J., Gwinn-Hardy, K., Lynch, T., Hardy, J. & Farrer, M. (1999) Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. Neuroreport, 10, 427-429.
Langlois, J.A., Rutland-Brown, W. & Thomas, K.E. (2004) Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations, and Deaths. National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA.
Larsen, C.N., Krantz, B.A. & Wilkinson, K.D. (1998) Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry, 37, 3358-3368.
Marin, R., Williams, A., Hale, S., Burge, B., Mense, M., Bauman, R. & Tortella, F. (2003) The effect of voluntary exercise exposure on histological and neurobehavioral outcomes after ischemic brain injury in the rat. Physiol. Behav., 80, 167-175.
Zemlan, F.P., Jauch, E.C., Mulchahey, J.J., Gabbita, S.P., Rosenberg, W.S., Speciale, S.G. & Zuccarello, M. (2002) C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome. Brain Res., 947, 131-139.
Nylén, K., Öst, M., Csajbok, L.Z., Nilsson, I., Hall, C., Blennow, K., Nellgård, B. & Rosengren, L. (2008) Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir. (Wein), 150, 221-227.
Choi, D.W. (2002) Exploratory clinical testing of neuroscience drugs. Nat. Neurosci. ( Suppl.), 5, 1023-1025. [doi: 10.1038/nn930]
Dambinova, S.A., Khounteev, G.A., Izykenova, G.A., Zavolokov, I.G., Ilyukhina, A.Y. & Skoromets, A.A. (2003) Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin. Chem., 49, 1752-1762.
Raabe, A., Grolms, C. & Seifert, V. (1999) Serum markers of brain damage and outcome prediction in patients after severe head injury. Br. J. Neurosurg., 13, 56-59.
Seubert, P., Larson, J., Oliver, M., Jung, M.W., Baudry, M. & Lynch, G. (1988) Stimulation of NMDA receptors induces proteolysis of spectrin in hippocampus. Brain Res., 460, 189-194.
Siman, R., Noszek, J.C. & Kegerise, C. (1989) Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage. J. Neurosci., 9, 1579-1590.
Siman, R., Zhang, C., Roberts, V.L., Pitts-Kiefer, A. & Neumar, R.W. (2005) Novel surrogate markers for acute brain damage: cerebrospinal fluid levels corrrelate with severity of ischemic neurodegeneration in the rat. J. Cereb. Blood Flow Metab., 25, 1433-1444.
Johnsson, P., Blomquist, S., Lührs, C., Malmkvist, G., Alling, C., Solem, J.O. & Ståhl, E. (2000) Neuron-specific enolase increases in plasma during and immediately after extracorporeal circulation. Ann. Thorac. Surg., 69, 750-754.
Ge, P., Luo, Y., Liu, C.L. & Hu, B. (2007) Protein aggregation and proteasome dysfunction after brain ischemia. Stroke, 38, 3230-3236.
Choi, S.C. & Bullock, R. (2001) Design and statistical issues in multicenter trials of severe head injury. Neurol. Res., 23, 190-192.
Sultana, R., Boyd-Kimball, D., Cai, J., Pierce, W.M., Klein, J.B., Merchant, M. & Butterfield, D.A. (2007) Proteomics analysis of the Alzheimer's disease hippocampal proteome. J. Alzheimers Dis., 11, 153-164.
Zaremba, J. & Losy, J. (2001) Early TNF-alpha levels correlate with ischemic stroke severity. Acta Neurol. Scand., 104, 288-295.
Ingebrigtsen, T. & Romner, B. (2003) Biochemical serum markers for brain damage: a short review
2004; 62
2006; 77
2005; 336
1981; 49
2005; 21
2008; 5
1988; 460
2008; 2
1996; 35
2001; 104
2005; 24
2007; 38
2005; 25
2003; 91
2000; 17
1997; 11
1999; 18
2005; 103
2004c; 21
2008; 25
2005; 73
1999; 13
2003; 49
1999; 10
2008; 65
2002; 947
2007; 24
2008; 150
2002; 39
2009; 68
2010; 38
2003; 80
2000; 69
2005; 233
2002; 5
1989; 9
2000; 20
1999; 23
1999; 22
2006; 5
1997; 28
2004
2001; 23
2004b; 21
2007; 11
2006; 117
1996; 10
2001; 21
1998; 37
1988; 1
1993; 679
2003; 70
2000; 36
2004a; 57
2004; 16
1995; 43
2003; 24
1989; 492
2005; 2
1992; 20
2001; 78
2007; 319
2003; 21
1998; 9
e_1_2_7_5_1
Berger R.P. (e_1_2_7_3_1) 2005; 103
e_1_2_7_9_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_60_1
e_1_2_7_17_1
e_1_2_7_62_1
e_1_2_7_15_1
e_1_2_7_41_1
e_1_2_7_64_1
e_1_2_7_43_1
e_1_2_7_66_1
e_1_2_7_11_1
e_1_2_7_45_1
e_1_2_7_47_1
e_1_2_7_26_1
e_1_2_7_49_1
e_1_2_7_28_1
Langlois J.A. (e_1_2_7_20_1) 2004
e_1_2_7_50_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_52_1
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_54_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_56_1
e_1_2_7_37_1
e_1_2_7_58_1
Ingebrigtsen T. (e_1_2_7_13_1) 2003; 21
e_1_2_7_39_1
e_1_2_7_6_1
e_1_2_7_4_1
Elkind M.S. (e_1_2_7_10_1) 2003; 70
e_1_2_7_8_1
e_1_2_7_18_1
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_61_1
e_1_2_7_2_1
e_1_2_7_14_1
e_1_2_7_42_1
e_1_2_7_63_1
e_1_2_7_12_1
e_1_2_7_44_1
e_1_2_7_65_1
e_1_2_7_46_1
e_1_2_7_48_1
e_1_2_7_27_1
e_1_2_7_29_1
e_1_2_7_51_1
e_1_2_7_30_1
e_1_2_7_53_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_55_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_57_1
e_1_2_7_36_1
e_1_2_7_59_1
e_1_2_7_38_1
References_xml – reference: Berger, R.P., Dulani, T., Adelson, P.D., Leventhal, J.M., Richichi, R. & Kochanek, P.M. (2006) Identification of inflicted traumatic brain injury in well-appearing infants using serum and cerebrospinal markers: a possible screening tool. Pediatrics, 117, 325-332.
– reference: Petzold, A., Keir, G., Kay, A., Kerr, M. & Thompson, E.J. (2006) Axonal damage and outcome in subarachnoid haemorrhage. J. Neurol. Neurosurg. Psychiatry, 77, 753-759.
– reference: Elkind, M.S. (2003) Stroke in the elderly. Mt. Sinai J. Med., 70, 27-37.
– reference: Missler, U., Wiesmann, M., Friedrich, C. & Kaps, M. (1997) S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke, 28, 1956-1960.
– reference: Marin, R., Williams, A., Hale, S., Burge, B., Mense, M., Bauman, R. & Tortella, F. (2003) The effect of voluntary exercise exposure on histological and neurobehavioral outcomes after ischemic brain injury in the rat. Physiol. Behav., 80, 167-175.
– reference: Johnsson, P., Blomquist, S., Lührs, C., Malmkvist, G., Alling, C., Solem, J.O. & Ståhl, E. (2000) Neuron-specific enolase increases in plasma during and immediately after extracorporeal circulation. Ann. Thorac. Surg., 69, 750-754.
– reference: Sultana, R., Boyd-Kimball, D., Cai, J., Pierce, W.M., Klein, J.B., Merchant, M. & Butterfield, D.A. (2007) Proteomics analysis of the Alzheimer's disease hippocampal proteome. J. Alzheimers Dis., 11, 153-164.
– reference: Siman, R., McIntosh, T.K., Soltesz, K.M., Chen, Z., Neumar, R.W. & Roberts, V.L. (2004) Proteins released from degenerating neurons are surrogate markers for acute brain damage. Neurobiol. Dis., 16, 311-320.
– reference: Langlois, J.A., Rutland-Brown, W. & Thomas, K.E. (2004) Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations, and Deaths. National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA.
– reference: Petzold, A. & Shaw, G. (2007) Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain. J. Immunol. Methods, 319, 34-40.
– reference: Seubert, P., Lee, K. & Lynch, G. (1989) Ischemia triggers NMDA receptor-linked cytoskeletal proteolysis in hippocampus. Brain Res., 492, 366-370.
– reference: Kobeissy, F.H., Ottens, A.K., Zhang, Z.Q., Dave, J.R., Tortella, F.C., Hayes, R.L. & Wang, K.K.W. (2006) Novel differential neuroproteomics analysis of traumatic brain injury in rats. Mol. Cell Proteomics, 5, 1887-1898.
– reference: Siman, R., Roberts, V.L., McNeil, E., Dang, A., Bavaria, J.E., Ramchandren, S. & McGarvey, M. (2008) Biomarker evidence for mild central nervous system injury after surgically-induced circulation arrest. Brain Res., 5, 1-11.
– reference: Dirnagl, U., Ladecola, C. & Moskowitz, M.A. (1999) Pathobiology of ischemic stroke: an integrated view. Trends Neurosci., 22, 391-397.
– reference: Pelinka, L.E., Kroepfl, A., Schmidhammer, R., Krenn, M., Buchinger, W., Redl, H. & Raabe, A. (2004a) Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J. Trauma, 57, 1006-1012.
– reference: Tongaonkar, P., Chen, L., Lambertson, D., Ko, B. & Madura, K. (2000) Evidence for an interaction between ubiquitin-conjugating enzymes and the 26S proteasome. Mol. Cell. Biol., 20, 4691-4698.
– reference: Pineda, J., Liu, M.C., Aikman, J., Akle, V., Lewis, S., Wang, K.K.W., Robertson, C. & Hayes, R.L. (2007) Clinical significance of αII-spectrin breakdown products in CSF after severe traumatic brain injury in human. J. Neurotrauma, 24, 354-366.
– reference: Siman, R., Zhang, C., Roberts, V.L., Pitts-Kiefer, A. & Neumar, R.W. (2005) Novel surrogate markers for acute brain damage: cerebrospinal fluid levels corrrelate with severity of ischemic neurodegeneration in the rat. J. Cereb. Blood Flow Metab., 25, 1433-1444.
– reference: Hu, B.R., Janelidze, S., Ginsberg, M.D., Busto, R., Perez-Pinzon, M., Sick, T.J., Siesjö, B.K. & Liu, C.L. (2001) Protein aggregation after focal brain ischemia and reperfusion. J. Cereb. Blood Flow Metab., 21, 865-875.
– reference: Seubert, P., Larson, J., Oliver, M., Jung, M.W., Baudry, M. & Lynch, G. (1988) Stimulation of NMDA receptors induces proteolysis of spectrin in hippocampus. Brain Res., 460, 189-194.
– reference: Shaw, G.J., Jauch, E.C. & Zemlan, F.P. (2002) Serum cleaved tau protein levels and clinical outcome in adult patients with closed head injury. Ann. Emerg. Med., 39, 254-257.
– reference: Yamazaki, Y., Yada, K., Morii, S., Kitahara, T. & Ohwada, T. (1995) Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. Surg. Neurol., 43, 267-270.
– reference: Jackson, P. & Thompson, R.J. (1981) The demonstration of new human brain-specific proteins by high-resolution two-dimensional polyacrylamide gel electrophoresis. J. Neurol. Sci., 49, 429-438.
– reference: Wilkinson, K.D., Deshpande, S. & Larsen, C.N. (1992) Comparisons of neuronal (PGP9.5) and non-neuronal ubiquitin C-terminal hydrolases. Biochem. Soc. Trans., 20, 631-637.
– reference: Ingebrigtsen, T. & Romner, B. (2003) Biochemical serum markers for brain damage: a short review with emphasis on clinical utility in mild head injury. Restor. Neurol. Neurosci., 21, 171-176.
– reference: Wilkinson, K.D. (1997) Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J., 11, 1245-1256.
– reference: Wang, K.K.W., Ottens, A., Liu, M.C., Lewis, S.B., Meegan, C., Oli, M.W., Tortella, F.C. & Hayes, R.L. (2005) Proteomic identification of biomarkers of traumatic brain injury. Expert Rev. Proteomics, 2, 603-614.
– reference: Vos, P.E., Lamers, K.J., Hendriks, J.C., Van Haaren, M., Beems, T., Zimmerman, C., Van Geel, W., De Reus, H., Biert, J. & Verbeek, M.M. (2004) Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology, 62, 1303-1310.
– reference: Papa, L., Akinyi, L., Liu, M.C., Pineda, J.A., Tepas, J.J., 3rd, Oli, M.W., Zheng, W., Robinson, G., Robicsek, S.A., Gabrielli, A., Heaton, S.C., Hannay, H.J., Demery, J.A., Brophy, G.M., Layon, J., Robertson, C.S., Hayes, R.L. & Wang, K.K. (2010) Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit. Care Med., 38, 138-144.
– reference: Berger, R.P., Beers, S.R., Richichi, R., Wiesman, D. & Adelson, P.D. (2007) Serum biomarker concentrations and outcome after pediatric traumatic brain injury. J. Neurotrauma, 24, 1793-1801.
– reference: Lumpkins, K.M., Bochicchio, G.V., Keledjian, K., Simard, J.M., McCunn, M. & Scalea, T. (2008) Glial fibrillary acidic protein is highly correlated with brain injury. J. Trauma, 65, 778-784.
– reference: Nylén, K., Öst, M., Csajbok, L.Z., Nilsson, I., Hall, C., Blennow, K., Nellgård, B. & Rosengren, L. (2008) Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir. (Wein), 150, 221-227.
– reference: Pike, B.R., Flint, J., Dave, J.R., Lu, X.C., Wang, K.K.W., Tortella, F.C. & Hayes, R.L. (2003) Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived αII-spectrin in CSF after middle cerebral artery occlusion in rats. J. Cereb. Blood Flow Metab., 24, 98-106.
– reference: Choi, D.W. (2002) Exploratory clinical testing of neuroscience drugs. Nat. Neurosci. ( Suppl.), 5, 1023-1025. [doi: 10.1038/nn930]
– reference: Pelinka, L.E., Szalay, L., Jafarmadar, M., Schmidhammer, R., Redl, H. & Bahrami, S. (2003) Circulating S100B is increased after bilateral femur fracture without brain injury in the rat. Br. J. Anaesth., 91, 595-597.
– reference: Ge, P., Luo, Y., Liu, C.L. & Hu, B. (2007) Protein aggregation and proteasome dysfunction after brain ischemia. Stroke, 38, 3230-3236.
– reference: Kwon, J., Mochida, K., Wang, Y.L., Sekiguchi, S., Sankai, T., Aoki, S., Ogura, A., Yoshikawa, Y. & Wada, K. (2005) Ubiquitin C-terminal hydrolase L-1 is essential for the early apoptotic wave of germinal cells and for sperm quality control during spermatogenesis. Biol. Reprod., 73, 29-35.
– reference: Roberts-Lewis, J.M. & Siman, R. (1993) Spectrin proteolysis in the hippocampus: a biochemical marker for neuronal injury and neuroprotection. Ann. N Y Acad. Sci., 679, 78-86.
– reference: Zemlan, F.P., Jauch, E.C., Mulchahey, J.J., Gabbita, S.P., Rosenberg, W.S., Speciale, S.G. & Zuccarello, M. (2002) C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome. Brain Res., 947, 131-139.
– reference: Pelinka, L.E., Harada, N., Szalay, L., Jafarmadar, M., Redl, H. & Bahrami, S. (2004c) Release of S100B differs during ischemia and reperfusion of the liver, the gut, and the kidney in rats. Shock, 21, 72-76.
– reference: Saigoh, K., Wang, Y.L., Suh, J.G., Yamanishi, T., Sakai, Y., Kiyosawa, H., Harada, T., Ichihara, N., Wakana, S., Kikuchi, T. & Wada, K. (1999) Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet., 23, 47-51.
– reference: Ross, S.A., Cunningham, R.T., Johnston, C.F. & Rowlands, B.J. (1996) Neuron-specific enolase as an aid to outcome prediction in head injury. Br. J. Neurosurg., 10, 471-476.
– reference: Zaremba, J. & Losy, J. (2001) Early TNF-alpha levels correlate with ischemic stroke severity. Acta Neurol. Scand., 104, 288-295.
– reference: Pike, B.R., Flint, J., Johnson, E., Glenn, C.C., Dutta, S., Wang, K.K.W. & Hayes, R.L. (2001) Accumulation of calpain-cleaved non-erythroid αII-spectrin in cerebrospinal fluid after traumatic brain injury in rats. J. Neurochem., 78, 1297-1306.
– reference: Dambinova, S.A., Khounteev, G.A., Izykenova, G.A., Zavolokov, I.G., Ilyukhina, A.Y. & Skoromets, A.A. (2003) Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin. Chem., 49, 1752-1762.
– reference: Siman, R., Noszek, J.C. & Kegerise, C. (1989) Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage. J. Neurosci., 9, 1579-1590.
– reference: Larsen, C.N., Price, J.S. & Wilkinson, K.D. (1996) Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry, 35, 6735-6744.
– reference: Choi, S.C. & Bullock, R. (2001) Design and statistical issues in multicenter trials of severe head injury. Neurol. Res., 23, 190-192.
– reference: Pike, B.R., Zhao, X., Newcomb, J.K., Posmantur, R.M., Wang, K.K. & Hayes, R.L. (1998) Regional calpain and caspase-3 proteolysis of alpha-spectrin after traumatic brain injury. Neuroreport, 9, 2437-2442.
– reference: Lincoln, S., Vaughan, J., Wood, N., Baker, M., Adamson, J., Gwinn-Hardy, K., Lynch, T., Hardy, J. & Farrer, M. (1999) Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. Neuroreport, 10, 427-429.
– reference: Raabe, A., Grolms, C. & Seifert, V. (1999) Serum markers of brain damage and outcome prediction in patients after severe head injury. Br. J. Neurosurg., 13, 56-59.
– reference: Johnston, S.C., Riddle, S.M., Cohen, R.E. & Hill, C.P. (1999) Structural basis for the specificity of ubiquitin C-terminal hydrolases. EMBO J., 18, 3877-3887.
– reference: Kobeissy, F.H., Sadasivan, S., Oli, M.W., Robinson, G., Larner, S.F., Zhang, Z., Hayes, R.L. & Wang, K.K.W. (2008) Neuroproteomics and systems biology-based discovery of protein biomarkers for traumatic brain injury and clinical validation. Proteomics Clin. Appl. 2, 1467-1483.
– reference: Shaw, G., Yang, C., Ellis, R., Anderson, K., Parker Mickle, J., Scheff, S., Pike, B., Anderson, D.K. & Howland, D.R. (2005) Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem. Biophys. Res. Commun., 336, 1268-1277.
– reference: Petzold, A. (2005) Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J. Neurol. Sci., 233, 183-198.
– reference: Ringger, N.C., O' Steen, B.E., Brabham, J.G., Silver, X., Pineda, J., Wang, K.K.W. & Hayes, R.L. (2005) A novel marker for traumatic brain injury: CSF αII-spectrin breakdown product levels. J. Neurotrauma, 21, 1443-1456.
– reference: Pelinka, L.E., Kroepfl, A., Leixnering, M., Buchinger, W., Raabe, A. & Redl, H. (2004b) GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J. Neurotrauma, 21, 1553-1561.
– reference: Berger, R.P., Adelson, P.D., Pierce, M.C., Dulani, T., Cassidy, L.D. & Kochanek, P.M. (2005) Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J. Neurosurg., 103(1 Suppl.), 61-68.
– reference: Larsen, C.N., Krantz, B.A. & Wilkinson, K.D. (1998) Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry, 37, 3358-3368.
– reference: McGinn, M.J., Kelley, B.J., Akinyi, L., Oli, M.W., Liu, M.C., Hayes, R.L., Wang, K.K.W. & Povlishock, J.T. (2009) Biochemical, structural and biomarker evidence for calpain-mediated cytoskeletal change following diffuse brain injury uncomplicated by contusion. J. Neuropathol. Exp. Neurol., 68, 241-249.
– reference: Siman, R. & Noszek, J.C. (1988) Excitatory amino acids activate calpain I and induce structural protein breakdown in vivo. Neuron, 1, 279-287.
– reference: Nath, R., Huggins, M., McGinnis, K., Nadimpalli, D. & Wang, K.K.W. (2000) Development and characterization of antibodies specific to caspase-3-produced αII-spectrin 120 kDa breakdown product: marker for neuronal apoptosis. Neurochem. Int., 36, 351-361.
– reference: Pelinka, L.E., Hertz, H., Mauritz, W., Harada, N., Jafarmadar, M., Albrecht, M., Redl, H. & Bahrami, S. (2005) Nonspecific increase of systemic neuron-specific enolase after trauma: clinical and experimental findings. Shock, 24, 119-123.
– reference: Romner, B., Ingebrigtsen, T., Kongstad, P. & Borgesen, S.E. (2000) Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings. J. Neurotrauma, 17, 641-647.
– reference: Anderson, K.J., Scheff, S.W., Miller, K.M., Roberts, K.N., Gilmer, L.K., Yang, C. & Shaw, G. (2008) The phosphorylated axonal form of the neurofilament subunit NF-H (pNF-H) as a blood biomarker of traumatic brain injury. J. Neurotrauma, 25, 1079-1085.
– volume: 2
  start-page: 1467
  year: 2008
  end-page: 1483
  article-title: Neuroproteomics and systems biology‐based discovery of protein biomarkers for traumatic brain injury and clinical validation
  publication-title: Proteomics Clin. Appl.
– volume: 233
  start-page: 183
  year: 2005
  end-page: 198
  article-title: Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss
  publication-title: J. Neurol. Sci.
– volume: 9
  start-page: 2437
  year: 1998
  end-page: 2442
  article-title: Regional calpain and caspase‐3 proteolysis of alpha‐spectrin after traumatic brain injury
  publication-title: Neuroreport
– volume: 49
  start-page: 429
  year: 1981
  end-page: 438
  article-title: The demonstration of new human brain‐specific proteins by high‐resolution two‐dimensional polyacrylamide gel electrophoresis
  publication-title: J. Neurol. Sci.
– volume: 23
  start-page: 190
  year: 2001
  end-page: 192
  article-title: Design and statistical issues in multicenter trials of severe head injury
  publication-title: Neurol. Res.
– volume: 1
  start-page: 279
  year: 1988
  end-page: 287
  article-title: Excitatory amino acids activate calpain I and induce structural protein breakdown in vivo
  publication-title: Neuron
– volume: 73
  start-page: 29
  year: 2005
  end-page: 35
  article-title: Ubiquitin C‐terminal hydrolase L‐1 is essential for the early apoptotic wave of germinal cells and for sperm quality control during spermatogenesis
  publication-title: Biol. Reprod.
– volume: 10
  start-page: 471
  year: 1996
  end-page: 476
  article-title: Neuron‐specific enolase as an aid to outcome prediction in head injury
  publication-title: Br. J. Neurosurg.
– volume: 104
  start-page: 288
  year: 2001
  end-page: 295
  article-title: Early TNF‐alpha levels correlate with ischemic stroke severity
  publication-title: Acta Neurol. Scand.
– volume: 336
  start-page: 1268
  year: 2005
  end-page: 1277
  article-title: Hyperphosphorylated neurofilament NF‐H is a serum biomarker of axonal injury
  publication-title: Biochem. Biophys. Res. Commun.
– volume: 947
  start-page: 131
  year: 2002
  end-page: 139
  article-title: C‐tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome
  publication-title: Brain Res.
– volume: 69
  start-page: 750
  year: 2000
  end-page: 754
  article-title: Neuron‐specific enolase increases in plasma during and immediately after extracorporeal circulation
  publication-title: Ann. Thorac. Surg.
– volume: 68
  start-page: 241
  year: 2009
  end-page: 249
  article-title: Biochemical, structural and biomarker evidence for calpain‐mediated cytoskeletal change following diffuse brain injury uncomplicated by contusion
  publication-title: J. Neuropathol. Exp. Neurol.
– volume: 65
  start-page: 778
  year: 2008
  end-page: 784
  article-title: Glial fibrillary acidic protein is highly correlated with brain injury
  publication-title: J. Trauma
– volume: 24
  start-page: 354
  year: 2007
  end-page: 366
  article-title: Clinical significance of αII‐spectrin breakdown products in CSF after severe traumatic brain injury in human
  publication-title: J. Neurotrauma
– volume: 21
  start-page: 1443
  year: 2005
  end-page: 1456
  article-title: A novel marker for traumatic brain injury: CSF αII‐spectrin breakdown product levels
  publication-title: J. Neurotrauma
– volume: 20
  start-page: 631
  year: 1992
  end-page: 637
  article-title: Comparisons of neuronal (PGP9.5) and non‐neuronal ubiquitin C‐terminal hydrolases
  publication-title: Biochem. Soc. Trans.
– volume: 18
  start-page: 3877
  year: 1999
  end-page: 3887
  article-title: Structural basis for the specificity of ubiquitin C‐terminal hydrolases
  publication-title: EMBO J.
– volume: 24
  start-page: 119
  year: 2005
  end-page: 123
  article-title: Nonspecific increase of systemic neuron‐specific enolase after trauma: clinical and experimental findings
  publication-title: Shock
– volume: 319
  start-page: 34
  year: 2007
  end-page: 40
  article-title: Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain
  publication-title: J. Immunol. Methods
– volume: 13
  start-page: 56
  year: 1999
  end-page: 59
  article-title: Serum markers of brain damage and outcome prediction in patients after severe head injury
  publication-title: Br. J. Neurosurg.
– volume: 9
  start-page: 1579
  year: 1989
  end-page: 1590
  article-title: Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage
  publication-title: J. Neurosci.
– volume: 117
  start-page: 325
  year: 2006
  end-page: 332
  article-title: Identification of inflicted traumatic brain injury in well‐appearing infants using serum and cerebrospinal markers: a possible screening tool
  publication-title: Pediatrics
– volume: 57
  start-page: 1006
  year: 2004a
  end-page: 1012
  article-title: Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma
  publication-title: J. Trauma
– volume: 39
  start-page: 254
  year: 2002
  end-page: 257
  article-title: Serum cleaved tau protein levels and clinical outcome in adult patients with closed head injury
  publication-title: Ann. Emerg. Med.
– volume: 5
  start-page: 1
  year: 2008
  end-page: 11
  article-title: Biomarker evidence for mild central nervous system injury after surgically‐induced circulation arrest
  publication-title: Brain Res.
– year: 2004
– volume: 49
  start-page: 1752
  year: 2003
  end-page: 1762
  article-title: Blood test detecting autoantibodies to ‐methyl‐D‐aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke
  publication-title: Clin. Chem.
– volume: 24
  start-page: 98
  year: 2003
  end-page: 106
  article-title: Accumulation of calpain and caspase‐3 proteolytic fragments of brain‐derived αII‐spectrin in CSF after middle cerebral artery occlusion in rats
  publication-title: J. Cereb. Blood Flow Metab.
– volume: 2
  start-page: 603
  year: 2005
  end-page: 614
  article-title: Proteomic identification of biomarkers of traumatic brain injury
  publication-title: Expert Rev. Proteomics
– volume: 22
  start-page: 391
  year: 1999
  end-page: 397
  article-title: Pathobiology of ischemic stroke: an integrated view
  publication-title: Trends Neurosci.
– volume: 21
  start-page: 171
  year: 2003
  end-page: 176
  article-title: Biochemical serum markers for brain damage: a short review with emphasis on clinical utility in mild head injury
  publication-title: Restor. Neurol. Neurosci.
– volume: 62
  start-page: 1303
  year: 2004
  end-page: 1310
  article-title: Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury
  publication-title: Neurology
– volume: 20
  start-page: 4691
  year: 2000
  end-page: 4698
  article-title: Evidence for an interaction between ubiquitin‐conjugating enzymes and the 26S proteasome
  publication-title: Mol. Cell. Biol.
– volume: 36
  start-page: 351
  year: 2000
  end-page: 361
  article-title: Development and characterization of antibodies specific to caspase‐3‐produced αII‐spectrin 120 kDa breakdown product: marker for neuronal apoptosis
  publication-title: Neurochem. Int.
– volume: 28
  start-page: 1956
  year: 1997
  end-page: 1960
  article-title: S‐100 protein and neuron‐specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke
  publication-title: Stroke
– volume: 460
  start-page: 189
  year: 1988
  end-page: 194
  article-title: Stimulation of NMDA receptors induces proteolysis of spectrin in hippocampus
  publication-title: Brain Res.
– volume: 43
  start-page: 267
  year: 1995
  end-page: 270
  article-title: Diagnostic significance of serum neuron‐specific enolase and myelin basic protein assay in patients with acute head injury
  publication-title: Surg. Neurol.
– volume: 5
  start-page: 1023
  issue: Suppl.
  year: 2002
  end-page: 1025
  article-title: Exploratory clinical testing of neuroscience drugs
  publication-title: Nat. Neurosci.
– volume: 70
  start-page: 27
  year: 2003
  end-page: 37
  article-title: Stroke in the elderly
  publication-title: Mt. Sinai J. Med.
– volume: 679
  start-page: 78
  year: 1993
  end-page: 86
  article-title: Spectrin proteolysis in the hippocampus: a biochemical marker for neuronal injury and neuroprotection
  publication-title: Ann. N Y Acad. Sci.
– volume: 38
  start-page: 138
  year: 2010
  end-page: 144
  article-title: Ubiquitin C‐terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury
  publication-title: Crit. Care Med.
– volume: 25
  start-page: 1079
  year: 2008
  end-page: 1085
  article-title: The phosphorylated axonal form of the neurofilament subunit NF‐H (pNF‐H) as a blood biomarker of traumatic brain injury
  publication-title: J. Neurotrauma
– volume: 21
  start-page: 1553
  year: 2004b
  end-page: 1561
  article-title: GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome
  publication-title: J. Neurotrauma
– volume: 21
  start-page: 72
  year: 2004c
  end-page: 76
  article-title: Release of S100B differs during ischemia and reperfusion of the liver, the gut, and the kidney in rats
  publication-title: Shock
– volume: 11
  start-page: 1245
  year: 1997
  end-page: 1256
  article-title: Regulation of ubiquitin‐dependent processes by deubiquitinating enzymes
  publication-title: FASEB J.
– volume: 16
  start-page: 311
  year: 2004
  end-page: 320
  article-title: Proteins released from degenerating neurons are surrogate markers for acute brain damage
  publication-title: Neurobiol. Dis.
– volume: 11
  start-page: 153
  year: 2007
  end-page: 164
  article-title: Proteomics analysis of the Alzheimer’s disease hippocampal proteome
  publication-title: J. Alzheimers Dis.
– volume: 103
  start-page: 61
  issue: 1 Suppl.
  year: 2005
  end-page: 68
  article-title: Serum neuron‐specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children
  publication-title: J. Neurosurg.
– volume: 38
  start-page: 3230
  year: 2007
  end-page: 3236
  article-title: Protein aggregation and proteasome dysfunction after brain ischemia
  publication-title: Stroke
– volume: 80
  start-page: 167
  year: 2003
  end-page: 175
  article-title: The effect of voluntary exercise exposure on histological and neurobehavioral outcomes after ischemic brain injury in the rat
  publication-title: Physiol. Behav.
– volume: 77
  start-page: 753
  year: 2006
  end-page: 759
  article-title: Axonal damage and outcome in subarachnoid haemorrhage
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 25
  start-page: 1433
  year: 2005
  end-page: 1444
  article-title: Novel surrogate markers for acute brain damage: cerebrospinal fluid levels corrrelate with severity of ischemic neurodegeneration in the rat
  publication-title: J. Cereb. Blood Flow Metab.
– volume: 78
  start-page: 1297
  year: 2001
  end-page: 1306
  article-title: Accumulation of calpain‐cleaved non‐erythroid αII‐spectrin in cerebrospinal fluid after traumatic brain injury in rats
  publication-title: J. Neurochem.
– volume: 35
  start-page: 6735
  year: 1996
  end-page: 6744
  article-title: Substrate binding and catalysis by ubiquitin C‐terminal hydrolases: identification of two active site residues
  publication-title: Biochemistry
– volume: 37
  start-page: 3358
  year: 1998
  end-page: 3368
  article-title: Substrate specificity of deubiquitinating enzymes: ubiquitin C‐terminal hydrolases
  publication-title: Biochemistry
– volume: 21
  start-page: 865
  year: 2001
  end-page: 875
  article-title: Protein aggregation after focal brain ischemia and reperfusion
  publication-title: J. Cereb. Blood Flow Metab.
– volume: 492
  start-page: 366
  year: 1989
  end-page: 370
  article-title: Ischemia triggers NMDA receptor‐linked cytoskeletal proteolysis in hippocampus
  publication-title: Brain Res.
– volume: 150
  start-page: 221
  year: 2008
  end-page: 227
  article-title: Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury
  publication-title: Acta Neurochir. (Wein)
– volume: 23
  start-page: 47
  year: 1999
  end-page: 51
  article-title: Intragenic deletion in the gene encoding ubiquitin carboxy‐terminal hydrolase in gad mice
  publication-title: Nat. Genet.
– volume: 24
  start-page: 1793
  year: 2007
  end-page: 1801
  article-title: Serum biomarker concentrations and outcome after pediatric traumatic brain injury
  publication-title: J. Neurotrauma
– volume: 10
  start-page: 427
  year: 1999
  end-page: 429
  article-title: Low frequency of pathogenic mutations in the ubiquitin carboxy‐terminal hydrolase gene in familial Parkinson’s disease
  publication-title: Neuroreport
– volume: 91
  start-page: 595
  year: 2003
  end-page: 597
  article-title: Circulating S100B is increased after bilateral femur fracture without brain injury in the rat
  publication-title: Br. J. Anaesth.
– volume: 5
  start-page: 1887
  year: 2006
  end-page: 1898
  article-title: Novel differential neuroproteomics analysis of traumatic brain injury in rats
  publication-title: Mol. Cell Proteomics
– volume: 17
  start-page: 641
  year: 2000
  end-page: 647
  article-title: Traumatic brain damage: serum S‐100 protein measurements related to neuroradiological findings
  publication-title: J. Neurotrauma
– volume: 21
  start-page: 171
  year: 2003
  ident: e_1_2_7_13_1
  article-title: Biochemical serum markers for brain damage: a short review with emphasis on clinical utility in mild head injury
  publication-title: Restor. Neurol. Neurosci.
– ident: e_1_2_7_19_1
  doi: 10.1095/biolreprod.104.037077
– ident: e_1_2_7_9_1
  doi: 10.1016/S0166-2236(99)01401-0
– ident: e_1_2_7_21_1
  doi: 10.1021/bi960099f
– ident: e_1_2_7_66_1
  doi: 10.1016/S0006-8993(02)02920-7
– ident: e_1_2_7_28_1
  doi: 10.1016/S0197-0186(00)00040-1
– ident: e_1_2_7_18_1
  doi: 10.1002/prca.200800011
– ident: e_1_2_7_54_1
  doi: 10.1523/JNEUROSCI.09-05-01579.1989
– ident: e_1_2_7_14_1
  doi: 10.1016/0022-510X(81)90032-0
– volume: 103
  start-page: 61
  issue: 1
  year: 2005
  ident: e_1_2_7_3_1
  article-title: Serum neuron‐specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children
  publication-title: J. Neurosurg.
– ident: e_1_2_7_39_1
  doi: 10.1097/00001756-199808030-00002
– ident: e_1_2_7_30_1
  doi: 10.1097/CCM.0b013e3181b788ab
– ident: e_1_2_7_37_1
  doi: 10.1016/j.jim.2006.09.021
– ident: e_1_2_7_8_1
  doi: 10.1373/49.10.1752
– ident: e_1_2_7_45_1
  doi: 10.1111/j.1749-6632.1993.tb18290.x
– ident: e_1_2_7_49_1
  doi: 10.1016/0006-8993(88)91222-X
– ident: e_1_2_7_31_1
  doi: 10.1093/bja/aeg225
– ident: e_1_2_7_36_1
  doi: 10.1016/j.jns.2005.03.015
– ident: e_1_2_7_46_1
  doi: 10.1089/089771500415391
– ident: e_1_2_7_17_1
  doi: 10.1074/mcp.M600157-MCP200
– ident: e_1_2_7_11_1
  doi: 10.1161/STROKEAHA.107.487108
– ident: e_1_2_7_27_1
  doi: 10.1161/01.STR.28.10.1956
– ident: e_1_2_7_33_1
  doi: 10.1089/neu.2004.21.1553
– ident: e_1_2_7_59_1
  doi: 10.1128/MCB.20.13.4691-4698.2000
– ident: e_1_2_7_22_1
  doi: 10.1021/bi972274d
– ident: e_1_2_7_6_1
  doi: 10.1038/nn930
– ident: e_1_2_7_43_1
  doi: 10.1080/02688699944195
– ident: e_1_2_7_48_1
  doi: 10.1038/12647
– ident: e_1_2_7_57_1
  doi: 10.1016/j.brainres.2008.03.034
– ident: e_1_2_7_58_1
  doi: 10.3233/JAD-2007-11203
– ident: e_1_2_7_53_1
  doi: 10.1016/0896-6273(88)90076-1
– ident: e_1_2_7_5_1
  doi: 10.1089/neu.2007.0316
– ident: e_1_2_7_61_1
  doi: 10.1586/14789450.2.4.603
– ident: e_1_2_7_38_1
  doi: 10.1136/jnnp.2005.085175
– ident: e_1_2_7_42_1
  doi: 10.1089/neu.2006.003789
– ident: e_1_2_7_56_1
  doi: 10.1038/sj.jcbfm.9600138
– ident: e_1_2_7_16_1
  doi: 10.1093/emboj/18.14.3877
– volume: 70
  start-page: 27
  year: 2003
  ident: e_1_2_7_10_1
  article-title: Stroke in the elderly
  publication-title: Mt. Sinai J. Med.
– ident: e_1_2_7_55_1
  doi: 10.1016/j.nbd.2004.03.016
– ident: e_1_2_7_15_1
  doi: 10.1016/S0003-4975(99)01393-4
– ident: e_1_2_7_47_1
  doi: 10.1080/02688699647104
– ident: e_1_2_7_51_1
  doi: 10.1067/mem.2002.121214
– ident: e_1_2_7_35_1
  doi: 10.1097/01.shk.0000168876.68154.43
– ident: e_1_2_7_40_1
  doi: 10.1046/j.1471-4159.2001.00510.x
– ident: e_1_2_7_62_1
  doi: 10.1096/fasebj.11.14.9409543
– ident: e_1_2_7_7_1
  doi: 10.1179/016164101101198325
– ident: e_1_2_7_12_1
  doi: 10.1097/00004647-200107000-00012
– ident: e_1_2_7_50_1
  doi: 10.1016/0006-8993(89)90921-9
– ident: e_1_2_7_64_1
  doi: 10.1016/0090-3019(95)80012-6
– ident: e_1_2_7_60_1
  doi: 10.1212/01.WNL.0000120550.00643.DC
– ident: e_1_2_7_65_1
  doi: 10.1034/j.1600-0404.2001.00053.x
– volume-title: Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations, and Deaths
  year: 2004
  ident: e_1_2_7_20_1
– ident: e_1_2_7_29_1
  doi: 10.1007/s00701-007-1489-2
– ident: e_1_2_7_52_1
  doi: 10.1016/j.bbrc.2005.08.252
– ident: e_1_2_7_63_1
  doi: 10.1042/bst0200631
– ident: e_1_2_7_4_1
  doi: 10.1542/peds.2005-0711
– ident: e_1_2_7_32_1
  doi: 10.1097/01.TA.0000108998.48026.C3
– ident: e_1_2_7_24_1
  doi: 10.1097/TA.0b013e318185db2d
– ident: e_1_2_7_26_1
  doi: 10.1097/NEN.0b013e3181996bfe
– ident: e_1_2_7_44_1
  doi: 10.1089/neu.2004.21.1443
– ident: e_1_2_7_23_1
  doi: 10.1097/00001756-199902050-00040
– ident: e_1_2_7_41_1
  doi: 10.1097/01.WCB.0000098520.11962.37
– ident: e_1_2_7_34_1
  doi: 10.1097/01.shk.0000101672.49265.14
– ident: e_1_2_7_2_1
  doi: 10.1089/neu.2007.0488
– ident: e_1_2_7_25_1
  doi: 10.1016/j.physbeh.2003.06.001
SSID ssj0008645
Score 2.353571
Snippet Ubiquitin C‐terminal hydrolase‐L1 (UCH‐L1), also called neuronal‐specific protein gene product 9.5, is a highly abundant protein in the neuronal cell body and...
Ubiquitin C-terminal hydrolase-L1 (UCH-L1), also called neuronal-specific protein gene product 9.5, is a highly abundant protein in the neuronal cell body and...
AbstractUbiquitin C-terminal hydrolase-L1 (UCH-L1), also called neuronal-specific protein gene product 9.5, is a highly abundant protein in the neuronal cell...
SourceID proquest
pubmed
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 722
SubjectTerms Animals
biomarker
Biomarkers - blood
Biomarkers - cerebrospinal fluid
Brain - metabolism
Brain Injuries - blood
Brain Injuries - cerebrospinal fluid
cell death
diagnosis
Disease Models, Animal
Infarction, Middle Cerebral Artery - blood
Infarction, Middle Cerebral Artery - cerebrospinal fluid
ischemia
Male
Rats
Rats, Sprague-Dawley
Spectrin - cerebrospinal fluid
stroke
traumatic brain injury
Ubiquitin Thiolesterase - blood
Ubiquitin Thiolesterase - cerebrospinal fluid
Title Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats
URI https://api.istex.fr/ark:/67375/WNG-6KKVTXLN-6/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1460-9568.2010.07097.x
https://www.ncbi.nlm.nih.gov/pubmed/20384815
https://www.proquest.com/docview/21500082
https://www.proquest.com/docview/733645648
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtQwFL1CZQEbCi2PlJcXqLuM8vRjWY1aqraaBerA7Cw7tsW0JYVJIrWs-AS-kS_B18kMmqpIFWLlKIqT-Po6Ptc5PhfgHXVaUEdtbFUm4oKXPNZFomJjKMPpW2Q6qH1O6OG0OJqVs4H_hHthen2I1YIbjozwvcYBrnRzc5AnMW53GxhaLBFshHgSqVuIjz78UZLiNOQrRnW1mKd0tk7qufVGazPVfTT61W0wdB3VhmnpYBPOlw3q2Sjno67Vo-r7Da3H_9Pix_BoQK9kr3e3J3DP1luwvVf7yP3LNdklgU8aFuq34MF4mUtuG8xUz79183Zek_GvHz8HBs4F-XxtFj62bqw_eZIS1RBFUBAAOUML4vE0mfvoG_n7RNWGtAvVBYlZojGzBZnXZ94lfEG8HzdPYXqwfzo-jIf8DnHlwyQWM2WNq5wzRZZpVeXcw5GCO997ieGFLVLhSkWTnOUCSQAa4V5lPN4RuaNOsfwZbNSXtX0BpNIeuVImKlGKQlCuqeFZqnPnC6sTFwFb9qWsBvFzzMFxIdeCoESicSUaVwbjyqsI0lXNr70AyB3q7AZ3WVXwVkMCHSvlp8l7SY-PP57OTiaSRvB26U_S9wj-q1G1vewa6ZFYgGcRkL9cgTqWqAXEI3jee-LqcVmSY5aEMgIa_OnOLy73jyZ4tPOvFV_Cw55egXyfV7DRLjr72qO2Vr8J4_E3awIyeg
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LctMwFL1T2kXZ8Gh5mFe1gO6c8VO2Fiw6aUvahCyYBLITki0NhuJA4gwJKz6B_-FXWPEl6MpOmHTKTIeZLljZ47FsWfde3yPr-FyAp1RLRjVVrhIBc6M0Tl0ZecLNc5pg-maBtGqffdoZRqejeLQBP5b_wtT6EKsPbhgZ9n2NAY4fpM9Huefi_24NRSvxWNKaNwzLrlp8MfO36fOTQ2PsZ0FwfDRod9ymxICbGaSeuIlQuc60zqMgkCILU5MRo1T7IfXyNFKRz3QsqBcmIcN1aImII8tNymWhplokobnuNdjCguIo3H_46o92VUpthWTUc3NTn47WaUQX9nwtN26hmecXAd91HG0T4fFN-Lkcwpr_8qE1q2Qr-3pOXfI_HeNbcKMB6OSgjqjbsKHKHdg9KEU1_rgg-8RSZu1axA5st5fl8nYhH8ri86yoipK0f3373pCMzsi7RT4ZmymKMgd7PhFTIghqHiAtakLMlIEU08yqNhBR5qSaiJlV0SUSi3eQonxvvN5siAnV6R0YXsmz34XNclyq-0AyacA5TVjGYhYxmkqap4EvQ202SnragWTpPDxr9N2xzMgZX5vneRyNydGY3BqTzx3wVy0_1Ronl2izb_1z1cCMGnIEk5i_6b_gtNt9PRj1-pw6sLd0YG4sgstRolTj2ZQbsGkRqAPkL2egVCfKHaUO3Ktdf3W7wAuxEETsALUOfOmO86PTPu49-NeGe7DdGbzs8d5Jv_sQrtdsEqQ3PYLNajJTjw1IreQT-zIg8PaqI-M3x9SOvg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtNAEB6VVgIu_LQUzF_3AL058u_ae-BQJQ1tE0UINZDbsmvvitDWKYkjEk48As_Dq3DjSdhZO0GpilQh9cDJluW11zsznm-9n78BeEG1ZFRT5SoRMDdK49SVkSfcPKcJpm8WSKv22aMH_ehoEA_W4MfiX5hKH2L5wQ0jw76vMcDPc30xyD0Xf3erGVqJx5LGrCZYdtT8i5m-TV4dtoytXwZBe_-4eeDWFQbczAD1xE2EynWmdR4FgRRZmJqEGKXaD6mXp5GKfKZjQb0wCRkuQ0sEHFluMi4LNdUiCc11b8CG6QfDshGtt3-kq1JqCySjnJub-nSwyiK6tOcrqXEDrTy7DPeuwmibB9t34ediBCv6y0ljWspG9vWCuOT_OcT34E4Nz8leFU_3YU0Vm7C1V4hydDYnu8QSZu1KxCbcai6K5W1B3pfDz9NhOSxI89e37zXF6JR8nOfjkZmgKHOw6xMxIYKg4gGSosbETBjIcJJZzQYiipyUYzG1GrpEYukOMiw-GZ83G2ICdfIA-tfy7NuwXowK9QhIJg00pwnLWMwiRlNJ8zTwZajNRklPO5AsfIdntbo7Fhk55SuzPI-jMTkak1tj8pkD_rLleaVwcoU2u9Y9lw3MqCFDMIn5-95rTjudd8eDbo9TB3YW_suNRXAxShRqNJ1wAzUt_nSA_OUMFOpEsaPUgYeV5y9vF3ghloGIHaDWf6_ccb5_1MO9x__acAduvmm1efew13kCtysqCXKbnsJ6OZ6qZwahlvK5fRUQ-HDdgfEbYpqNbQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ubiquitin+C%E2%80%90terminal+hydrolase%E2%80%90L1+as+a+biomarker+for+ischemic+and+traumatic+brain+injury+in+rats&rft.jtitle=The+European+journal+of+neuroscience&rft.au=Liu%2C+Ming+C.&rft.au=Akinyi%2C+Linnet&rft.au=Scharf%2C+Dancia&rft.au=Mo%2C+Jixiang&rft.date=2010-02-01&rft.issn=0953-816X&rft.eissn=1460-9568&rft.volume=31&rft.issue=4&rft.spage=722&rft.epage=732&rft_id=info:doi/10.1111%2Fj.1460-9568.2010.07097.x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_j_1460_9568_2010_07097_x
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0953-816X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0953-816X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0953-816X&client=summon